Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of homoharringtonine in treating patients who have refractory acute promyelocytic leukemia.

Key facts

Study ID

NCT00030355

Run by

National Cancer Institute (NCI)

People needed

0

Last updated by the study team

2013-03-22

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.